Lanreotide autogel in acromegaly – a decade on

Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly

(2014) G. Lombardi et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism

(2013) Akira Shimatsu et al.   ENDOCRINE JOURNAL

Effects of Lanreotide Autogel on Growth Hormone, Insulinlike Growth Factor 1, and Tumor Size in Acromegaly: A 1-Year Prospective Multicenter Study

(2013) Roberto Attanasio et al.   Endocrine Practice

A Comprehensive Study of Clinical, Biochemical, Radiological, Vascular, Cardiac, and Sleep Parameters in an Unselected Cohort of Patients With Acromegaly Undergoing Presurgical Somatostatin Receptor Ligand Therapy

(2013) Anand K. Annamalai et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial

(2013) Philippe J. Caron et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry

(2013) Roberto Salvatori et al.   Pituitary

A novel mass spectrometry-based method for determining insulin-like growth factor 1: assessment in a cohort of subjects with newly diagnosed acromegaly

(2012) Richard Kay et al.   CLINICAL ENDOCRINOLOGY

Oral Octreotide Absorption in Human Subjects: Comparable Pharmacokinetics to Parenteral Octreotide and Effective Growth Hormone Suppression

(2012) S. Tuvia et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pharmacodynamic Modeling of the Effects of Lanreotide Autogel on Growth Hormone and Insulin-Like Growth Factor 1

(2011) María J. Garrido et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly

(2011) Yasemin Tutuncu et al.   Pituitary

Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal

(2010) Renata S Auriemma et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone

(2010) Aart-Jan van der Lely et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Efficacy and Acceptability of Lanreotide Autogel® 120 mg at Different Dose Intervals in Patients with Acromegaly Previously Treated with Octreotide LAR

(2010) J. Schopohl et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

A Consensus on Criteria for Cure of Acromegaly

(2010) A. Giustina et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Current therapy and drug pipeline for the treatment of patients with acromegaly

(2009) Sampath Satish Kumar et al.   ADVANCES IN THERAPY

A Single-Center Open-Label Study to Investigate the Efficacy and Safety of Repeated Subcutaneous Injections of Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide

(2009) Phillip Kelly et al.   Endocrine Practice

The German ACROSTUDY: past and present

(2009) M Buchfelder et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Guidelines for Acromegaly Management: An Update

(2009) S. Melmed et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review

(2009) Gherardo Mazziotti et al.   Pituitary

Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly

(2009) Roberto Salvatori et al.   Pituitary

Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension

(2009) Shlomo Melmed et al.   Pituitary

Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48weeks in patients with acromegaly

(2008) Philippe Chanson et al.   CLINICAL ENDOCRINOLOGY

Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly

(2008) Annamaria Colao et al.   CLINICAL ENDOCRINOLOGY

Population Pharmacokinetic Analysis of Lanreotide Autogel® in Healthy Subjects

(2008) Iñaki F Trocóniz et al.   CLINICAL PHARMACOKINETICS

A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly

(2008) I M Holdaway et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Quantitative analysis of somatostatin receptor subtypes (1–5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR

(2008) Giselle F Taboada et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly

(2008) Robert D. Murray et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Molecular Origin of the Self-Assembly of Lanreotide into Nanotubes: A Mutational Approach

(2007) Céline Valéry et al.   BIOPHYSICAL JOURNAL

Mortality in Acromegaly: A Metaanalysis

(2007) O. M. Dekkers et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM